相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。18F-Florbetapir PET in Patients with Frontotemporal Dementia and Alzheimer Disease
Christopher Kobylecki et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?
Andrew D. Watt et al.
ACTA NEUROPATHOLOGICA (2014)
Lessons from a BACE1 inhibitor trial: Off-site but not off base
Debomoy K. Lahiri et al.
ALZHEIMERS & DEMENTIA (2014)
A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease
Eric Karran et al.
ANNALS OF NEUROLOGY (2014)
[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease
Shizuo Hatashita et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease
Ilie-Cosmin Stancu et al.
FASEB JOURNAL (2014)
Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects
Robert Vassar et al.
JOURNAL OF NEUROCHEMISTRY (2014)
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease
Lars Lannfelt et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
Active immunotherapy options for Alzheimer's disease
Bengt Winblad et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
Niklas Mattsson et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2014)
Safety, tolerability and immunogenicity of an immunotherapeutic vaccine (vanutide cridificar [ACC-001]) and the QS-21 adjuvant in Japanese individuals with mild-to-moderate Alzheimer's disease: A phase IIa, multicenter, randomized, adjuvant and placebo clinical trial
Heii Arai et al.
Alzheimers & Dementia (2013)
The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): Study design and progress
Miia Kivipelto et al.
ALZHEIMERS & DEMENTIA (2013)
The Therapeutics of Alzheimer's Disease: Where We Stand and Where We Are Heading
J. Dennis et al.
ANNALS OF NEUROLOGY (2013)
Comparing Positron Emission Tomography Imaging and Cerebrospinal Fluid Measurements of β-Amyloid
Susan M. Landau et al.
ANNALS OF NEUROLOGY (2013)
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the ?-secretase inhibitor avagacestat
Gary Tong et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans
Biljana Georgievska et al.
JOURNAL OF NEUROCHEMISTRY (2013)
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
Victor L. Villemagne et al.
LANCET NEUROLOGY (2013)
Alzheimer disease therapy-moving from amyloid-β to tau
Ezio Giacobini et al.
NATURE REVIEWS NEUROLOGY (2013)
Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease
David J. Irwin et al.
FRONTIERS IN AGING NEUROSCIENCE (2013)
Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
Jens Moreth et al.
IMMUNITY & AGEING (2013)
Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat
Charles F. Albright et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
Susanne Ostrowitzki et al.
ARCHIVES OF NEUROLOGY (2012)
Amyloid-β-Associated Clinical Decline Occurs Only in the Presence of Elevated P-tau
Rahul S. Desikan et al.
ARCHIVES OF NEUROLOGY (2012)
Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
Vladimir Coric et al.
ARCHIVES OF NEUROLOGY (2012)
Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men
Gary Tong et al.
CLINICAL DRUG INVESTIGATION (2012)
A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects
Randy Dockens et al.
CLINICAL PHARMACOKINETICS (2012)
A Population-Based Clinicopathological Study in the Oldest-Old: The 90+Study
Maria M. Corrada et al.
CURRENT ALZHEIMER RESEARCH (2012)
The mechanism of γ-Secretase dysfunction in familial Alzheimer disease
Lucia Chavez-Gutierrez et al.
EMBO JOURNAL (2012)
Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons
Peer-Hendrik Kuhn et al.
EMBO JOURNAL (2012)
Solanezumab for the treatment of mild-to-moderate Alzheimer's disease
Bruno P. Imbimbo et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2012)
Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors
Ian Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
γ-Secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment
Ting Li et al.
JOURNAL OF NEUROCHEMISTRY (2012)
An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ
Oskar Adolfsson et al.
JOURNAL OF NEUROSCIENCE (2012)
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study (vol 11, pg 669, 2012)
C. M. Clark et al.
LANCET NEUROLOGY (2012)
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Iryna Benilova et al.
NATURE NEUROSCIENCE (2012)
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
Ronald B. DeMattos et al.
NEURON (2012)
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
Christopher M. Clark et al.
LANCET NEUROLOGY (2012)
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann et al.
ALZHEIMERS & DEMENTIA (2011)
Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease
P. Hemachandra Reddy
BRAIN RESEARCH (2011)
Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor
Patrick C. May et al.
JOURNAL OF NEUROSCIENCE (2011)
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial (vol 7, pg 483, 2008)
G. K. Wilcock et al.
LANCET NEUROLOGY (2011)
Functional network disruption in the degenerative dementias
Michela Pievani et al.
LANCET NEUROLOGY (2011)
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
Eric Karran et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
A novel pathway for amyloid precursor protein processing
Erik Portelius et al.
NEUROBIOLOGY OF AGING (2011)
Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration
Ming Jin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease
Ronald S. Black et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2010)
Total and phosphorylated tau protein as biological markers of Alzheimer's disease
Harald Hampel et al.
EXPERIMENTAL GERONTOLOGY (2010)
Revising the definition of Alzheimer's disease: a new lexicon
Bruno Dubois et al.
LANCET NEUROLOGY (2010)
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack et al.
LANCET NEUROLOGY (2010)
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Kaj Blennow et al.
NATURE REVIEWS NEUROLOGY (2010)
Decreased Clearance of CNS β-Amyloid in Alzheimer's Disease
Kwasi G. Mawuenyega et al.
SCIENCE (2010)
The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?
Kerensa Broersen et al.
ALZHEIMERS RESEARCH & THERAPY (2010)
Prevention of Dementia by Intensive Vascular Care (PreDIVA) A Cluster-randomized Trial in Progress
Edo Richard et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2009)
Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
Bruno Vellas et al.
CURRENT ALZHEIMER RESEARCH (2009)
Angiogenesis: A Team Effort Coordinated by Notch
L. -K. Phng et al.
DEVELOPMENTAL CELL (2009)
Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease
Anne M. Fagan et al.
EMBO MOLECULAR MEDICINE (2009)
Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease
David B. Henley et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease A Randomized Controlled Trial
Robert C. Green et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Peter T. Nelson et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2009)
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Kurt R. Brunden et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S. Salloway et al.
NEUROLOGY (2009)
Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics
Matthew L. Hemming et al.
PLOS ONE (2009)
Amyloid-beta immunisation for Alzheimer's disease
Thomas Wisniewski et al.
LANCET NEUROLOGY (2008)
Antibody capture of soluble A beta does not reduce cortical A beta amyloidosis in the PDAPP mouse
Peter Seubert et al.
NEURODEGENERATIVE DISEASES (2008)
Progress in the active immunotherapeutic approach to Alzheimer's disease: Clinical investigations into AN1792-Associated meningoencephalitis
Michael Pride et al.
NEURODEGENERATIVE DISEASES (2008)
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial
Gordon K. Wilcock et al.
LANCET NEUROLOGY (2008)
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial (vol 7, pg 483, 2008)
[Anonymous]
LANCET NEUROLOGY (2008)
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Aβ species in amyloid precursor protein transgenic mice
Irina Petrushina et al.
JOURNAL OF NEUROSCIENCE (2007)
Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-β after inhibition of γ-secretase
Eric R. Siemers et al.
CLINICAL NEUROPHARMACOLOGY (2007)
Safety, tolerability, pharmacokinetics, and Aβ levels after short-term administration of R-flurbiprofen in healthy elderly individuals
Douglas R. Galasko et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2007)
CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment -: A follow-up study
G. Li et al.
NEUROLOGY (2007)
Cerebrospinal fluid β-amyloid 1-42 concentration may predict cognitive decline in older women
Deborah R. Gustafson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
Absence of β-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia
Stephanie Bombois et al.
ARCHIVES OF NEUROLOGY (2007)
In vitro and in vivo profiling of CHF5022 and CHF5074 -: Two β-amyloid1-42 lowering agents
Bruno P. Imbimbo et al.
PHARMACOLOGICAL RESEARCH (2007)
Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults
Anne M. Fagan et al.
ARCHIVES OF NEUROLOGY (2007)
Memantine in the treatment of mild-to-moderate Alzheimer's disease
Kelly M. Cosman et al.
EXPERT OPINION ON PHARMACOTHERAPY (2007)
Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly
Erik Stomrud et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2007)
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders
Carlo Ballatore et al.
NATURE REVIEWS NEUROSCIENCE (2007)
Bace1 modulates myelination in the central and peripheral nervous system
Xiangyou Hu et al.
NATURE NEUROSCIENCE (2006)
Aβ species removal after Aβ42 immunization
James A. R. Nicoll et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2006)
Concentration-dependent modulation of amyloid-β in vivo and in vitro using the γ-secretase inhibitor, LY-450139
Thomas A. Lanz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Control of peripheral nerve myelination by the β-secretase BACE1
Michael Willem et al.
SCIENCE (2006)
Amyloid-β peptide remnants in AN-1792-immunized Alzheimer's disease patients -: A biochemical analysis
R. Lyle Patton et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Novel therapeutic opportunities for Alzheimer's disease:: focus on nonsteroidal anti-inflammatory drugs
KP Townsend et al.
FASEB JOURNAL (2005)
Synthesis and biological activity of flurbiprofen analogues as selective inhibitors β-amyloid1-42 secretion
I Peretto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor proteintransgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β
MM Racke et al.
JOURNAL OF NEUROSCIENCE (2005)
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
AJ Bayer et al.
NEUROLOGY (2005)
Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease
E Masliah et al.
NEUROLOGY (2005)
Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures
TA Lanz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Multi-compartmental pharmacodynamic assessment of the functional gamma-secretase inhibitor LY450139 in PDAPP transgenic mice and non-transgenic mice
PC May et al.
NEUROBIOLOGY OF AGING (2004)
Reduction in A-beta(1-40) and A-beta(1-42) in CSF and plasma in the beagle dog following acute oral dosing of the γ secretase inhibitor, LY450139
PA Hyslop et al.
NEUROBIOLOGY OF AGING (2004)
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia
AP Weng et al.
SCIENCE (2004)
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease
I Ferrer et al.
BRAIN PATHOLOGY (2004)
Lessons from the AN 1792 Alzheimer vaccine:: lest we forget
SR Robinson et al.
NEUROBIOLOGY OF AGING (2004)
Evidence supporting a role for anti-Aβ antibodies in the treatment of Alzheimer's disease
D Morgan et al.
NEUROBIOLOGY OF AGING (2004)
Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β42 production by direct modulation of γ-secretase activity
S Weggen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
JM Orgogozo et al.
NEUROLOGY (2003)
Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β
M Hoshi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease
C Hock et al.
NEURON (2003)
Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease
P Giannakopoulos et al.
NEUROLOGY (2003)
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide:: a case report
JAR Nicoll et al.
NATURE MEDICINE (2003)
Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds
I Skoog et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2003)
Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability
KN Dahlgren et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
RB DeMattos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Midlife vascular risk factors and Alzheimer's disease in later life:: longitudinal, population based study
M Kivipelto et al.
BMJ-BRITISH MEDICAL JOURNAL (2001)
Targeting small Aβ oligomers:: the solution to an Alzheimer's disease conundrum?
WL Klein et al.
TRENDS IN NEUROSCIENCES (2001)
Neurodegenerative tauopathies
VMY Lee et al.
ANNUAL REVIEW OF NEUROSCIENCE (2001)
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
C Janus et al.
NATURE (2000)
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
D Morgan et al.
NATURE (2000)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
Evidence that the β-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Aβ by zinc
MP Cuajungco et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Vascular risk factors for Alzheimer's disease: An epidemiologic perspective
MMB Breteler
NEUROBIOLOGY OF AGING (2000)
分享论文
